Boston Trust Walden Corp Lowers Holdings in Haemonetics Corporation $HAE

Key Points

• Boston Trust Walden Corp reduced its stake in Haemonetics Corporation by 2.5%, now owning approximately 1,089,940 shares valued at $81.32 million.
• Haemonetics reported a quarterly earnings of $1.10 EPS, exceeding estimates, despite a 4.4% decline in revenue compared to last year.
• Analysts have adjusted their price targets for Haemonetics, with a consensus target price of $75.89, indicating a shift in market sentiment towards the stock.

Boston Trust Walden Corp lessened its stake in Haemonetics Corporation (NYSE:HAE - Free Report) by 2.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,089,940 shares of the medical instruments supplier's stock after selling 28,391 shares during the quarter. Boston Trust Walden Corp owned 2.27% of Haemonetics worth $81,320,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently modified their holdings of the stock. Verdence Capital Advisors LLC raised its position in shares of Haemonetics by 3.6% in the 2nd quarter. Verdence Capital Advisors LLC now owns 6,216 shares of the medical instruments supplier's stock worth $464,000 after purchasing an additional 214 shares during the last quarter. CWM LLC raised its position in Haemonetics by 53.5% in the 2nd quarter. CWM LLC now owns 1,827 shares of the medical instruments supplier's stock worth $136,000 after buying an additional 637 shares during the last quarter. Vanguard Personalized Indexing Management LLC purchased a new position in Haemonetics in the 2nd quarter worth about $336,000. Hunter Perkins Capital Management LLC purchased a new stake in shares of Haemonetics during the 2nd quarter valued at about $530,000. Finally, Fort Washington Investment Advisors Inc. OH increased its position in shares of Haemonetics by 0.3% during the 2nd quarter. Fort Washington Investment Advisors Inc. OH now owns 518,682 shares of the medical instruments supplier's stock valued at $38,699,000 after purchasing an additional 1,596 shares during the last quarter. Hedge funds and other institutional investors own 99.67% of the company's stock.

Haemonetics Stock Up 2.9%

Shares of HAE stock opened at $50.25 on Tuesday. The stock has a 50 day moving average of $53.14 and a 200 day moving average of $63.08. The company has a current ratio of 1.72, a quick ratio of 1.04 and a debt-to-equity ratio of 1.04. The stock has a market cap of $2.42 billion, a P/E ratio of 15.37, a P/E/G ratio of 0.90 and a beta of 0.37. Haemonetics Corporation has a twelve month low of $47.31 and a twelve month high of $94.99.

Haemonetics (NYSE:HAE - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.10 EPS for the quarter, beating the consensus estimate of $1.01 by $0.09. The company had revenue of $321.39 million for the quarter, compared to analyst estimates of $305.12 million. Haemonetics had a return on equity of 26.64% and a net margin of 12.14%.Haemonetics's quarterly revenue was down 4.4% compared to the same quarter last year. During the same period last year, the company earned $1.02 earnings per share. Haemonetics has set its FY 2026 guidance at 4.700-5.00 EPS. As a group, sell-side analysts expect that Haemonetics Corporation will post 4.55 EPS for the current year.

Analysts Set New Price Targets

HAE has been the subject of a number of recent research reports. Citigroup cut their price objective on Haemonetics from $78.00 to $64.00 and set a "buy" rating for the company in a research note on Tuesday, October 7th. Baird R W raised Haemonetics to a "strong-buy" rating in a report on Wednesday, June 25th. JPMorgan Chase & Co. restated a "neutral" rating and set a $62.00 price target (down previously from $85.00) on shares of Haemonetics in a report on Friday, August 8th. Raymond James Financial lowered Haemonetics from a "strong-buy" rating to an "outperform" rating and decreased their price target for the company from $105.00 to $78.00 in a report on Monday, August 11th. Finally, Weiss Ratings reiterated a "hold (c-)" rating on shares of Haemonetics in a research note on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $75.89.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.